Andrew Ho

Andrew Ho has work experience in the field of scientific consulting and research. Andrew is currently working as a Scientific Consultant at Epirium, where they collaborate with contract research organizations (CROs) to design and optimize preclinical studies. Andrew also works closely with teams specialized in pharmacokinetics, drug modeling, and biodistribution studies. Prior to this, Andrew worked as a Research Scientist at Faculté des Sciences - Université Paris Cité, where they focused on rare congenital muscle diseases. Andrew analyzed patient genomic data to identify disease-specific signatures and developed liquid biopsy assays and strategies for drug lead development. Before that, Andrew was a Scientific Consultant at Myoforte Therapeutics Inc., where they were involved in designing and refining preclinical studies for drug efficacy validation. Andrew also conducted data control and analysis and played a crucial role in the company's growth. Andrew began their career as a Senior Scientist at Stanford University School of Medicine, where they focused on neuromuscular and muscle inflammatory biology. Andrew guided multiple research projects, supervised students, and implemented innovative biotechnologies for validating therapeutic target leads. Andrew'saccomplishments include the implementation of single-cell time-lapse imaging and bioluminescent in vivo imaging.

Andrew Ho completed their Doctor of Philosophy (PhD) in Biochemistry, Biophysics, and Molecular Biology at the University of Toronto from 2000 to 2006.